The most advanced FXR agonist in clinical development is obeticholic acid [6,7], which was approved by the US Food and Drug Administration (FDA) for the treatment primary biliary cholangitis (PBC) in 2016, and which is currently being investigated in clinical evaluation for the treatment of NAFLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.